Adnan Bashar, Md. Harisul Hoque, M. Chowdhury, A. Hasan, Khurshed Ahmed
{"title":"Antiplatelet Therapy in Patients with Acute Coronary Syndrome: An Update","authors":"Adnan Bashar, Md. Harisul Hoque, M. Chowdhury, A. Hasan, Khurshed Ahmed","doi":"10.3329/uhj.v17i1.50884","DOIUrl":null,"url":null,"abstract":"Antiplatelet therapy is the cornerstone in the treatment of acute coronary syndrome. Aspirin is the most widely used antiplatelet agent followed by P2Y12 inhibitors. Glycoprotein (GP) IIb-IIIa antagonists are also gaining popularity as an antiplatelet agents during peri-PCI period. This review article summarizes the indications, duration of dual antiplatelet therapy (DAPT) in ACS setting. Antiplatelet therapy in special situations like atrial fibrillation and thrombocytopenia are discussed here. Issues like switching between P2Y12 inhibitors and genetic testing of antiplatelet agents are also mentioned in this article \nUniversity Heart Journal Vol. 17, No. 1, Jan 2021; 66-70","PeriodicalId":23424,"journal":{"name":"University Heart Journal","volume":"36 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"University Heart Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3329/uhj.v17i1.50884","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Antiplatelet therapy is the cornerstone in the treatment of acute coronary syndrome. Aspirin is the most widely used antiplatelet agent followed by P2Y12 inhibitors. Glycoprotein (GP) IIb-IIIa antagonists are also gaining popularity as an antiplatelet agents during peri-PCI period. This review article summarizes the indications, duration of dual antiplatelet therapy (DAPT) in ACS setting. Antiplatelet therapy in special situations like atrial fibrillation and thrombocytopenia are discussed here. Issues like switching between P2Y12 inhibitors and genetic testing of antiplatelet agents are also mentioned in this article
University Heart Journal Vol. 17, No. 1, Jan 2021; 66-70
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
